Inspira Technologies OXY B.H.N. Ltd (NASDAQ: IINN)

Inspira Technologies OXY B.H.N. Ltd., a company that trades under the symbol INSP on the Nasdaq stock exchange, operates in the medical device industry with a focus on developing innovative life support technologies. The company's mission is to revolutionize the global mechanical ventilator market, which is projected to reach $19 billion by 2030, by creating technologies that treat patients while they are awake and deliver oxygen directly into their blood.

Inspira Technologies' primary product is the INSPIRA ART (Gen 2) device, an adaptive blood oxygenation technology designed to measure a patient's blood parameters in real-time continuously. This device delivers the required oxygen volume straight into the blood, equipped with the HYLA Blood Sensor, which scans the patient's blood continuously, enabling real-time detection of changes in patient condition. The INSPIRA ART (Gen 2) device bypasses the sick lungs, delivering oxygen directly to the body's organs, thereby reducing the need for mechanical ventilation, which is associated with increased risks, costs, and mortality rates. By using this device, patients' length of stay and costs in the ICU, rehabilitation period in the hospital, and re-admissions can be reduced compared to mechanical ventilation.

Inspira Technologies operates in a competitive landscape, primarily competing with companies that offer FDA-approved treatments. The company's INSPIRA ART (Gen 2) device has several competitive advantages, including providing a less invasive and traumatic alternative to mechanical ventilation, allowing patients to be treated while staying awake and breathing spontaneously, and minimizing the risk of developing common complications associated with mechanical ventilation. The device is designed to work in tandem with the underperforming lung, supporting the patient while they are being treated for their underlying medical condition.

Although the company has not disclosed specific customers, it has announced several partnerships and collaborations with medical institutions and companies. Inspira Technologies has received several grants and awards, including a grant from the Israeli Innovation Authority (IIA) for the VORTX Disposable Blood Oxygenation Technology. The company has also received ISO 13485:2016 Standard Certification, which is the international standard for quality management systems within the medical device industry.

Inspira Technologies' go-to-market strategy is based on providing affordable products, based on a razor-blade business model of disposables and software licensing to maximize its market reach while enhancing affordability and accessibility to medical care worldwide. The company is pursuing worldwide regulatory approvals, collaborating with leading medical centers and health organizations, identifying potential customer profiles, and investing in marketing and public relations to increase awareness of its solution.

The company's intellectual property portfolio consists of five patent families that include three granted patents, one US allowed application, three International Patent Applications (PCT), and eighteen pending patent applications. The company relies on trade secrets, know-how, and continuing innovation to develop and maintain its competitive position.